Cargando…
Nobody dares stopping clinical research, not even COVID-19
In the global health emergency caused by the COVID-19, clinical trial management has proven to be critical for the pharmaceutical industry, sponsors, and healthcare professionals. Our experience as a sponsor managing interventional oncology clinical studies has provided us with some data and insight...
Autores principales: | Malfettone, Andrea, Di Cosimo, Serena, Pérez-García, José Manuel, García, Alicia, Sampayo-Cordero, Miguel, Mina, Leonardo, Herrero, Carolina, Llombart-Cussac, Antonio, Cortés, Javier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8032688/ https://www.ncbi.nlm.nih.gov/pubmed/33833237 http://dx.doi.org/10.1038/s41523-021-00249-1 |
Ejemplares similares
-
Surrogate endpoints for early-stage breast cancer: a review of the state of the art, controversies, and future prospects
por: Gion, María, et al.
Publicado: (2021) -
The Value of Case Reports in Systematic Reviews from Rare Diseases. The Example of Enzyme Replacement Therapy (ERT) in Patients with Mucopolysaccharidosis Type II (MPS-II)
por: Sampayo-Cordero, Miguel, et al.
Publicado: (2020) -
The Impact of Excluding Nonrandomized Studies From Systematic Reviews in Rare Diseases: “The Example of Meta-Analyses Evaluating the Efficacy and Safety of Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis”
por: Sampayo-Cordero, Miguel, et al.
Publicado: (2021) -
Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019
por: Di Cosimo, Serena, et al.
Publicado: (2020) -
Dapagliflozin in patients with COVID-19: truth or dare
por: Rossello, Xavier, et al.
Publicado: (2021)